Neuropeptide–GPCR Regulation of the Neuroimmune Axis in Neurodegeneration: Mechanisms and Translation
Bioconjugate Chemistry · 2026
DOI: 10.1021/acs.bioconjchem.5c00637 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Xiaoting Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Insti…. Hauptthemen laut MEDLINE: Neuropeptides, Neurodegenerative Diseases, Receptors, G-Protein-Coupled, Neuroimmunomodulation. Die Arbeit nennt 127 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic neuroinflammation and dysfunction of the neuro-glial-vascular unit (NGVU) are central mechanisms driving the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Neuropeptides, as key regulatory signaling molecules in the central nervous system (CNS), bind to specific G protein-coupled receptors (GPCRs) on the surfaces of microglia, astrocytes, oligodendrocytes, and cerebrovascular elements. Through cell type-specific biased signaling, they precisely regulate the threshold for inflammatory activation, coordinate phagocytosis and autophagy, maintain metabolic homeostasis, and support the function of the blood-brain barrier. This review systematically analyzes the immune-regulatory roles of key neuropeptides, including neuropeptide Y (NPY), vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide (VIP/PACAP), substance P (SP), and calcitonin gene-related peptide (CGRP). We focus on how these systems contribute to CNS homeostasis and disease-relevant processes, including myelin repair and neuroinflammatory regulation. Integrating evidence from preclinical models and human samples, it clarifies the pathological mechanisms linking these neuropeptides to disease progression. The review also outlines a translational research pathway focused on ligand structure engineering, targeted delivery, and biomarker-guided patient stratification, emphasizing receptor subtype selectivity and CNS permeability for precise therapy. By integrating the neuropeptide-mediated neuro-immune network, this work offers new insights into immune pathology in neurodegenerative diseases and provides a foundation for next-generation immune regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Scien…
- Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi 315300, Ch…
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Department of Human Genetics, Ruhr University of Bochum, D-44801 Bochum, Germany.
ORCID-Profile: Hongying Bao, Wenzhi Ren, Aiguo Wu, Juan Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Bao, H., Hu, J., Ren, W., He, Z., Yu-Taeger, L., Wu, A., & Li, J. (2026). Neuropeptide–GPCR Regulation of the Neuroimmune Axis in Neurodegeneration: Mechanisms and Translation. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00637
Vancouver
Zhang X, Bao H, Hu J, Ren W, He Z, Yu-Taeger L, et al. Neuropeptide–GPCR Regulation of the Neuroimmune Axis in Neurodegeneration: Mechanisms and Translation. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.5c00637
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoting and Bao, Hongying and Hu, Jiayi and Ren, Wenzhi and He, Zhen and Yu-Taeger, Libo and Wu, Aiguo and Li, Juan},
title = {Neuropeptide–GPCR Regulation of the Neuroimmune Axis in Neurodegeneration: Mechanisms and Translation},
journal = {Bioconjugate Chemistry},
year = {2026},
doi = {10.1021/acs.bioconjchem.5c00637}
}
EUVIMED